cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.
Company profile
Ticker
CTIC
Exchange
Website
CEO
Adam Craig
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CELL THERAPEUTICS INC
SEC CIK
Corporate docs
IRS number
911533912
CTIC stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
6 Jul 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
Transcripts
CTIC
Earnings call transcript
2022 Q4
6 Mar 23
CTIC
Earnings call transcript
2022 Q3
8 Nov 22
CTIC
Earnings call transcript
2022 Q2
9 Aug 22
CTIC
Earnings call transcript
2022 Q1
12 May 22
CTIC
Earnings call transcript
2021 Q2
6 Aug 21
CTIC
Earnings call transcript
2021 Q1
2 Jun 21
CTIC
Earnings call transcript
2020 Q4
17 Mar 21
CTIC
Earnings call transcript
2020 Q3
10 Nov 20
CTIC
Earnings call transcript
2018 Q3
1 Nov 18
CTIC
Earnings call transcript
2018 Q2
2 Aug 18
Latest ownership filings
4
MARK N LAMPERT
28 Jun 23
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
28 Jun 23
4
MATTHEW D PERRY
26 Jun 23
4
Diane L. Parks
26 Jun 23
4
Laurent Fischer
26 Jun 23
4
Reed Vaughn Tuckson
26 Jun 23
4
Michael A Metzger
26 Jun 23
4
David Ross Parkinson
26 Jun 23
4
DAVID KIRSKE
26 Jun 23
4
Adam R Craig
26 Jun 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.21 mm | 24.21 mm | 24.21 mm | 24.21 mm | 24.21 mm | 24.21 mm |
Cash burn (monthly) | 2.07 mm | 6.06 mm | 3.08 mm | 4.49 mm | 10.37 mm | 6.86 mm |
Cash used (since last report) | 24.74 mm | 72.40 mm | 36.78 mm | 53.71 mm | 123.89 mm | 81.98 mm |
Cash remaining | -534.27 k | -48.19 mm | -12.57 mm | -29.50 mm | -99.68 mm | -57.77 mm |
Runway (months of cash) | -0.3 | -8.0 | -4.1 | -6.6 | -9.6 | -8.4 |
Institutional ownership, Q2 2023
12.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 1 |
Closed positions | 127 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.15 bn |
Total shares | 16.91 mm |
Total puts | 12.50 k |
Total calls | 51.02 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities V | 9.61 mm | $51.24 mm |
Stonepine Capital Management | 7.02 mm | $28.70 mm |
California State Teachers Retirement System | 126.41 k | $530.91 mm |
Ubs Global Asset Management Americas | 92.70 k | $389.34 mm |
Teacher Retirement System Of Texas | 31.27 k | $131.00 k |
Wolverine Trading | 15.76 k | $66.41 mm |
LGEN Legal & General | 9.34 k | $84.90 mm |
Biotechnology Value Fund L P | 0.00 | $0.00 |
FNY Investment Advisers | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.08 | 80,000 | 326.40 k | 0 |
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.49 | 80,000 | 359.20 k | 0 |
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.3 | 80,000 | 264.00 k | 0 |
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1 | 126,000 | 126.00 k | 0 |
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.8411 | 120,000 | 100.93 k | 0 |
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.61 | 60,000 | 276.60 k | 0 |
26 Jun 23 | Parkinson David Ross | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.07 | 50,000 | 203.50 k | 0 |
26 Jun 23 | Reed Vaughn Tuckson | Common Stock | Dispose U | No | No | 9.1 | 48,639 | 442.61 k | 0 | |
26 Jun 23 | Reed Vaughn Tuckson | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.08 | 80,000 | 326.40 k | 0 |
26 Jun 23 | Reed Vaughn Tuckson | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.49 | 80,000 | 359.20 k | 0 |